Intensity Therapeutics Inc
Veridion Score
Composite trend over time
Why is INTS moving today?
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for INTS.
INTS insider activity
Intensity Therapeutics Inc
2 insiders bought in the last 90 days
Net buying: $253K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-01 | 2026-06-30 | Wesolowski John M | Insider | buy | $3.48 | 3,688 | 7,102 | $13K | SEC Form 4 |
| 2026-07-01 | 2026-06-30 | Talamo Joseph | Insider | buy | $3.48 | 1,093 | 2,239 | $4K | SEC Form 4 |
| 2026-03-30 | 2026-03-26 | BENDER LEWIS H | Insider | buy | $6.11 | 37,749 | 118,549 | $231K | SEC Form 4 |
| 2026-01-05 | 2025-12-31 | Wesolowski John M | Insider | buy | $0.26 | 8,918 | 85,354 | $2K | SEC Form 4 |
| 2026-01-05 | 2025-12-31 | Talamo Joseph | Insider | buy | $0.26 | 14,482 | 28,661 | $4K | SEC Form 4 |
INTS contract awards, year to date.
Public federal awards linked to this ticker.
INTS lobbying filings, year to date.
Registered lobbying filings matched to Intensity Therapeutics Inc.